AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
AZN Chart
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback
On July 27, AstraZeneca PLC will report its results for the second quarter of 2026. As a reminder, its revenue rose 12.5% year-over-year to $15.29 billion in Q1. Enhertu, one of the key growth drivers of AstraZeneca's oncology franchise, generated $831 million in revenue in Q1, up 39.4% YoY and 4.1% QoQ.
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal Pharmaceutical. The Cambridge-based drugmaker could pay a further $900 million if the treatment hits certain development, regulatory and sales targets.
AstraZeneca PLC American Depositary Shares Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 30,501 | $6.02M | $5.16M | -$853,198.75 | -14.18% |
| CE Curtis Ellergodt Rothschild Investment LLC | 1,141 | $200,245.5 | $193,114.25 | -$7,131.25 | -3.56% |
| WH William Herlihy RESOURCES MANAGEMENT Corp. /CT/ /ADV | 175 | $30,712.5 | $29,618.75 | -$1,093.75 | -3.56% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 99,814 | $19.68M | $16.9M | -$2.79M | -14.15% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 10,874 | $2.14M | $1.84M | -$305,559.4 | -14.25% |
AstraZeneca PLC American Depositary Shares (AZN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AstraZeneca PLC American Depositary Shares ever had a stock split?
AstraZeneca PLC American Depositary Shares Profile
| Pharmaceuticals Industry | Healthcare Sector | Pascal Claude Roland Soriot CEO | NASDAQ (NGS) Exchange | G0593M107 CUSIP |
| GB Country | 94,300 Employees | 20 Feb 2026 Last Dividend | 27 Jul 2015 Last Split | - IPO Date |
Overview
AstraZeneca PLC, established as Zeneca Group PLC before its name change in April 1999, is a biopharmaceutical entity recognized for its deep involvement in the health sector. Since its incorporation in 1992, the company has centered its prowess on the discovery, development, management, and commercialization of prescription medicines. Holding its headquarters in Cambridge, United Kingdom, AstraZeneca has expanded its reach globally, touching the markets of the United Kingdom, the Americas, Europe, Asia, Africa, and Australasia. Through a network of distributors and local representative offices, it caters to the essential needs of both primary care and specialty care physicians. Furthermore, AstraZeneca upholds strategic collaboration agreements, such as with Neurimmune AG for the development of NI006, and with BenevolentAI targeting drug discovery in systemic lupus erythematosus, underlining its commitment to healthcare innovation and partnerships to tackle diverse health challenges.
Products and Services
Cardiovascular, Renal, and Metabolism Products: AstraZeneca offers a range of medicines including Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, and Farxiga, designed to address various health concerns within cardiovascular, renal, and metabolic diseases. These pharmaceuticals represent the company's focus on developing treatments that aim to improve patient outcomes in these critical areas of medicine.
Oncology: The company's oncology segment features drugs like Orpathys, Truqap, Zoladex, Faslodex, enhancing its footing in the field with innovative solutions for cancer treatment and management, showcasing AstraZeneca's significant contributions to advancing cancer care.
Respiratory and Immunology: Products such as Fasenra, Breztri, Symbicort, Saphnelo, and Tezspire cater to a wide range of respiratory conditions, including COPD and asthma, emphasizing AstraZeneca's role in developing drugs that significantly improve the lives of people living with these conditions.
Covid-19 and Rare Diseases: The development and provision of Vaxzevria and Beyfortus for Covid-19, alongside Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for various rare diseases, reflect AstraZeneca's flexible approach towards global health crises and its dedication to addressing less common but equally critical health challenges.
Partnerships for Drug Development: AstraZeneca's collaborative efforts, such as with Neurimmune AG for the development of NI006 and BenevolentAI for drug discovery in systemic lupus erythematosus, highlight its strategy to leverage external expertise and technology to broaden its research and development capabilities, aiming to deliver innovative therapeutic options to patients faster.
